Invivyd Inc. (IVVD) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Invivyd Inc. $0.61, price $0.92, upside -33.7%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Invivyd Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.3580 – $56.08 · fair‑value band $0.3995 – $0.7650 · the $0.9231 price screens above the $0.6120 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Invivyd in your weekly email
Every Wednesday you see whether Invivyd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
Show more
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Stock analysis
Invivyd Inc. (IVVD) currently trades at $0.9231, while our model-based Fair Value estimate is $0.6120, implying the stock looks roughly 50.8% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $0.3995 (bear) to $0.7650 (bull), the price of $0.9231 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Invivyd Inc. reported revenue of $53.4M in FY2025 versus $0 in FY2021. Reported net income was −$52.5M in FY2025.
Key figures
Market cap $296M · P/S ratio 4.07 · EPS (TTM) $−0.3100 · Net margin −98.2% · Return on equity −95.9% · Return on assets (EBIT) −70.2% · Operating margin −321% · Revenue (TTM) $58.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 68% below its 52-week high and 73% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −34%, IVVD screens richer than that median.
Fair Value models
Bear $0.3995Fair Value $0.6120Bull $0.7650
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score41 · Below median
Fair Value upside−34% · Above median
Profitability
Return on assets−46% · Bottom 25%
Net margin (TTM)−184% · Bottom 25%
Growth and dividend
Revenue growth21% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.22× · Cheaper than median
P/S (TTM)5.07× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Invivyd Inc. Fair Value". https://www.fairvalue-calculator.com/stock/IVVD
Frequently asked questions
Is Invivyd Inc. (IVVD) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.6120 versus a price of $0.9231, about −34% upside (overvalued).
What is the fair value of IVVD?
Our model-based fair value for Invivyd Inc. is $0.6120 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.9231.
What is the quality score of IVVD?
Invivyd Inc. has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Invivyd Inc. (IVVD)?
Our model-based price target is the fair value of $0.6120 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.3995, optimistic scenario $0.7650. It is a calculation from audited fundamentals, not an analyst target.
What is the Invivyd Inc. stock forecast for 2026?
Our models put fair value at $0.6120, about −34% upside versus a price of $0.9231 (overvalued). Cautious scenario $0.3995, optimistic scenario $0.7650. The calculation is refreshed regularly with new filings.
What is the revenue of Invivyd Inc. (IVVD)?
Invivyd Inc. reported trailing-twelve-month revenue of about $58.4M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Invivyd Inc. (IVVD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Invivyd Inc. it is $0.6120 per share (as of Sep 24, 2026), against a price of $0.9231. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Invivyd Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, IVVD trades above its calculated fair value: price $0.9231, fair value $0.6120, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IVVD?
No. The price is what the market pays today ($0.9231); the fair value is what the company's own numbers justify ($0.6120). For Invivyd Inc. the two are $0.3111 per share apart. That gap is exactly why we show both numbers side by side.
How much is Invivyd Inc. worth?
The market values Invivyd Inc. at about $296M (market capitalisation, as of Sep 24, 2026). Per share that is $0.9231; our models calculate a fair value of $0.6120 per share.
What do the bullish and bearish scenarios say about IVVD?
Our models span a range for Invivyd Inc.: cautious scenario $0.3995, base $0.6120, optimistic $0.7650 per share (as of Sep 24, 2026, price $0.9231). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Invivyd Inc. (IVVD)?
Balance-sheet figures for Invivyd Inc. (as of Sep 24, 2026): return on equity −95.9%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is IVVD from its 52-week high?
Invivyd Inc. trades at $0.9231, about 68% below its 52-week high of $2.88 and 73% above the low of $0.5350 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6120 is for.
Which stocks are comparable to Invivyd Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Invivyd Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price $0.9231, calculated fair value $0.6120 (−34%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IVVD calculated?
We run Invivyd Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.6120, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Invivyd Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Invivyd Inc. (IVVD)?
The closing price on Sep 23, 2026 was $0.9231. Our model-based fair value is $0.6120, about −34% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Invivyd Inc. right now?
The price sits above even our optimistic bull case ($0.7650). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3995 to $0.7650) leaves room in how you read the outcome.
Key figures of Invivyd Inc.
How large is the market capitalisation of Invivyd Inc. (IVVD)?
The market capitalisation of Invivyd Inc. is $296M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Invivyd Inc. (IVVD)?
The price-to-sales ratio of Invivyd Inc. is 4.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Invivyd Inc. (IVVD)?
Earnings per share at Invivyd Inc. are $−0.3100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Invivyd Inc. (IVVD)?
The net margin of Invivyd Inc. is −98.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Invivyd Inc. (IVVD)?
The return on equity (ROE) of Invivyd Inc. is −95.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Invivyd Inc. (IVVD)?
On an EBIT basis the return on assets of Invivyd Inc. is −70.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Invivyd Inc. (IVVD)?
The operating margin of Invivyd Inc. is −321% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Invivyd Inc. (IVVD)?
Revenue at Invivyd Inc. is growing +21.2% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Invivyd Inc. (IVVD) generate?
The free cash flow of Invivyd Inc. is −$58.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Invivyd Inc. (IVVD) hold?
Invivyd Inc. holds more cash than debt, $224M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Invivyd Inc. in the live analysis
One click puts Invivyd Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026